[1] Yan M, Parker BA, Schwab R, et al. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014 Jul;40(6):770-80. [2] Yang G, Yang Y, Liu R, et al. First-line immunotherapy or angiogenesis inhibitor plus chemothera...
在耶鲁CLIA实验室,使用Leica Bond III Refine polymer DAB Detection和HER2/ErbB2 clone EP3 Epitomics 1:100,上以低pH提取40分钟(图2A)。Rimm Lab则使用1.28 μg/mL的HER2/ErbB2 29D8(克隆29D8,#2165,Cell Signaling Technology)和压力煮沸容器(PT ...
HER2突变非小细胞肺癌常见于不吸烟者和女性 HER2突变非小细胞肺癌（NSCLC）是一个特殊的亚型，约占所有NSCLC患者的1%-4%。这种突变常见于不吸烟者和女性中，并且与其他基因突变（如EGFR、ALK等）相互排斥[1]。HER2突变会导致癌细胞快速生长和扩散，使得治疗变得更加复杂和具有挑战性。2 HER2突变缺乏针对性疗法，亟待...
[5] Fukushige S I, Matsubara K I, Yoshida M, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line[J]. Molecular and Cellular Biology, 1986, 6(3): 955-958. [6] Slamon D J, Clark G M, Wong...
lines, comprising the following steps: 1) the gene encoding HER2 inserted into eukaryotic expression vector multicloning site, to obtain a recombinant expression vector; 2) The recombinant expression obtained in step 1 vector into a host cell, screened to obtain a cell line stably expressing HER2...
将抗HER2的一抗(克隆29D8,Cell Signaling)用于组织,在4 ℃下以7种不同浓度/稀释度(0.000128 μg/mL~12.8 μg/mL)与细胞角蛋白(CK)以1:100稀释(单克隆小鼠抗人细胞角蛋白,克隆AE1/AE3;广谱筛选,Dako,Glostrup,Denmark)过夜孵育。使用的二抗包括anti-rabbit EnVision试剂(Dako)和anti-mouse Alexa Fluor 546...
7. Park, S. et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18, 160–170 (2010).8. Taylor, C. et al. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin. Cancer Res. 13, 5133–5143...
2、Kim, Ji-Yeon et al. “Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?.” Frontiers in oncology vol. 11 759150. 21 Oct. 2021, doi:10.3389/...
20. Li BT, Smit EF, Goto Y, et al. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2022;386(3):241-251. 21. Egbert Smit,et al.Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC...
[2]. NCCN Guideline non-small cell lung cancer V4.2022 [3]. CSCO 非小细胞肺癌诊疗指南(2023版) [4]. Zheng R, Zhang S, Zeng H, et al.. Cancer incidence and mortality in China, 2016. J Natl Cancer Cent, 2022, 2(1): 1-9. doi: 10.1016/j.jncc.2022.02.002 ...